US Stock MarketDetailed Quotes
KRBP Kiromic BioPharma
- 1.000
- -0.090-8.26%
15min DelayClose Nov 25 16:00 ET
1.55MMarket Cap-160P/E (TTM)
1.040High1.000Low646Volume1.040Open1.090Pre Close654.61Turnover0.06%Turnover RatioLossP/E (Static)1.55MShares3.78052wk High-0.17P/B1.15MFloat Cap0.18052wk Low--Dividend TTM1.15MShs Float555.000Historical High--Div YieldTTM3.67%Amplitude0.160Historical Low1.013Avg Price1Lot Size
Kiromic BioPharma Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 63.06%-1.93M | -26.59%-8.18M | -38.09%-5.7M | 10.61%-21.23M | -31.85%-5.41M | 14.25%-5.23M | -8.26%-6.46M | 45.55%-4.13M | -16.85%-23.75M | 55.24%-4.1M |
| Net income from continuing operations | -77.25%-7.43M | -0.90%-6.83M | -16.00%-6.15M | 39.68%-20.95M | 33.62%-4.69M | 64.64%-4.19M | 19.81%-6.76M | 28.07%-5.3M | -35.73%-34.73M | 33.54%-7.07M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 87.90%-12.8K | ---- |
| Depreciation and amortization | -1.60%552K | 1.46%557K | 0.18%557K | 32.73%2.22M | 0.04%555.1K | 4.55%561K | 37.56%549K | 204.16%556K | 256.19%1.67M | 306.82%554.9K |
| Other non cash items | 153.54%159K | -69.53%156K | -26.67%154K | -84.54%574.8K | -95.65%149.8K | -321.97%-297K | 4,671.43%512K | 39.63%210K | --3.72M | --3.44M |
| Change In working capital | 437.84%4.47M | -164.44%-2.1M | -182.86%-319K | -173.53%-3.21M | 9.18%-1.48M | -127.98%-1.32M | -141.87%-793K | 161.66%385K | 515.22%4.37M | -454.77%-1.63M |
| -Change in receivables | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 65.31%16.2K | --0 |
| -Change in prepaid assets | 33.56%601K | 108.29%45K | -58.95%-666K | -127.07%-179.3K | -50.23%332.7K | 346.04%450K | -736.58%-543K | -557.92%-419K | 159.28%662.4K | 170.45%668.5K |
| -Change in payables and accrued expense | 347.91%4.03M | -1,791.43%-1.99M | -47.15%501K | -160.07%-2.45M | 23.69%-1.66M | -132.22%-1.63M | -105.84%-105K | 260.95%948K | 124.08%4.07M | -253.67%-2.18M |
| -Change in other current liabilities | -7.43%-159K | -7.59%-156K | -6.94%-154K | -53.53%-586.8K | -26.09%-149.8K | -12.38%-148K | -957.99%-145K | 3.10%-144K | ---382.2K | ---118.8K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 63.06%-1.93M | -26.61%-8.18M | -38.06%-5.7M | 10.61%-21.23M | -31.85%-5.41M | 14.25%-5.23M | -8.24%-6.46M | 45.53%-4.13M | -16.85%-23.75M | 55.24%-4.1M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -123.47%-219K | -98K | -21K | 95.75%-206.6K | -157.35%-108.6K | -174.02%-98K | 0 | 0 | -168.69%-4.87M | 96.15%-42.2K |
| Capital expenditure reported | ---- | ---- | ---- | 95.77%-206.6K | ---- | ---- | ---- | ---- | ---4.88M | ---- |
| Net PPE purchase and sale | -123.47%-219K | ---98K | ---21K | --0 | -97.97%98K | -174.02%-98K | --0 | --0 | 100.79%15K | 540.93%4.84M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -123.47%-219K | ---98K | ---21K | 95.75%-206.6K | -157.35%-108.6K | -174.02%-98K | --0 | --0 | -168.69%-4.87M | 96.15%-42.2K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -85.33%1.03M | 23.48%8.78M | 11.83%6.19M | 514.72%23.99M | -0.36%4.34M | 6,193.12%7M | 4,263.35%7.11M | 3,380.21%5.54M | -89.55%3.9M | 858.47%4.36M |
| Net issuance payments of debt | -85.39%1.03M | 40.86%8.78M | 6.08%6.19M | 471.40%23.44M | -4.70%4.34M | 6,217.49%7.03M | 3,749.88%6.23M | 3,557.94%5.84M | 4,349.78%4.1M | 902.46%4.56M |
| Net common stock issuance | --0 | ---- | ---- | --659.1K | --100 | --0 | ---- | ---- | --0 | --0 |
| Net other financing activities | ---- | ---- | ---- | 44.40%-111.2K | ---1.2K | ---28K | --218K | ---300K | 93.06%-200K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -85.33%1.03M | 23.48%8.78M | 11.83%6.19M | 514.72%23.99M | -0.36%4.34M | 6,193.12%7M | 4,263.35%7.11M | 3,380.21%5.54M | -89.55%3.9M | 858.47%4.36M |
| Net cash flow | ||||||||||
| Beginning cash position | 54.55%4.18M | 78.97%3.68M | 396.74%3.2M | -97.46%645.2K | 912.25%4.38M | -58.47%2.7M | -86.42%2.05M | -97.46%645K | 149.78%25.35M | -98.77%432.7K |
| Current changes in cash | -167.00%-1.12M | -22.62%503K | -66.50%472K | 110.36%2.56M | -653.51%-1.18M | 127.58%1.68M | 107.55%650K | 113.77%1.41M | -262.52%-24.71M | 102.17%212.5K |
| End cash Position | -30.23%3.06M | 54.55%4.18M | 78.97%3.68M | 396.59%3.2M | 396.59%3.2M | 912.25%4.38M | -58.47%2.7M | -86.42%2.05M | -97.46%645.2K | -97.46%645.2K |
| Free cash flow | 59.62%-2.15M | -28.12%-8.28M | -38.57%-5.72M | 25.13%-21.43M | -32.65%-5.52M | 10.70%-5.33M | 23.46%-6.46M | 58.97%-4.13M | -28.85%-28.63M | 59.47%-4.16M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data